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A history of insulin
The discovery of insulin in 1921 by
Banting, Collip, MacLeod and Best was one
of the medical breakthroughs of this
century. These first insulins were of animal
origin, excreted from the pancreata of cows
and pigs. Addition of protamine and zinc
allowed the development of longer acting
insulins that were developed by 1951. By
1972, insulins were purer and this made
them less immunogenic with a more reliable
onset and duration of action. In the early
1980s, genetic engineering allowed the
production of insulin identical to human
insulin by bacteria and yeast.1,2
Indications for insulin therapy
All patients with Type I diabetes require
replacement insulin therapy upon onset of
the disease.3,4 Most patients with Type II
diabetes initially secrete enough insulin to
be treated with diet, exercise and oral
hypoglycaemic agents. However as the
disease progresses, the secretory capacity
falls making insulin treatment necessary.
About 50% of patients require insulin due
to beta-cell exhaustion. Other indications
for insulin include pregnancy, ill health
precluding oral treatment, during and after
major surgery, any illness that may place
the body in a stress situation, fasting blood
glucose of more than 17mmol/l on
diagnosis and diabetic ketoacidosis or
hyperosmolar coma.3,5,6
 The aims of treatment with insulin, are
whether Type I or Type II diabetes mellitus
are:
response to insulin.8,9 Since many patients
require a combination of intermediate or
long acting insulin with short acting
insulin, ready mixed insulin in the form of
biphasic insulins are available.6
Fast acting analogues (insulin lispro,
insulin aspart), have been developed in an
attempt to mimic physiology more closely.
Conventional soluble insulin forms
hexamers when in solution. These need to
dissociate before absorption and this
delays the onset of action. The newer
analogues are monomeric insulins and do
not associate. These insulins start to act
within 15 minutes of injection, peak at 50
minutes and have a duration of action of 3-
5 hours, which more closely resembles
human insulin. They are therefore
administered immediately before a
carbohydrate meal and this is likely to
enhance patient compliance.2,6,16
All insulins available within the GHS
are human in origin. The two forms of
biosynthetic recombinant DNA insulins
using Eschericia coli (Lilly) and
Saccharomyces cerevisiae (Novo-Nordisk)
are therapeutically equivalent.17 One should
also keep in mind that insulins from
foreign countries may be of animal origin.
It is important that there is no inadvertent
exchange of insulins. When in doubt,
human insulin should be used.18
All locally available insulins are of the
100 unit strength implying that they
contain 100 units of insulin per millilitre
(ml). Therefore care must be taken to
instruct the patient about the correct dose
in units and not in millilitres (mls) of
insulin. One must also exercise caution
when instructing tourists since different
strengths of insulin may still be available
internationally - 40 units/ml or 500 units/
ml.17
Designing insulin regimens
There is no generally accepted
approach to initiating insulin therapy and
much depends on the preferences of the
diabetologist. An empiric way of
calculating the dose may be the following:7
A) Type I: Initial dose:
0.5-0.8U/kg
B) Type II: With ketosis, during illness: 1-
1.5U/kg
C) Type II: Adolescents in growth phase:
1-1.5I/kg
D) Type II: With insulin resistance:
0.7-2.5U/kg
Different dosing regimens may be
administered and these are tailored
according to the patient’s motivation, the
ability to monitor control and adjust doses
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Insulin is required for normal carbohydrate, protein and fat
metabolism. Patients with Type I diabetes depend on
exogenous insulin for their survival while Type II diabetics
may require insulin at a later stage of their disease.
a) to achieve optimum metabolic control by
mimicking production of endogenous
insulin as closely as possible
b) to avoid experience and risks of
hypoglycaemia.4
Types of insulin
Since insulin is a protein that is acted
upon by the gastrointestinal enzymes, it
must be administered parenterally. Insulins
may be classified depending on their
pharmacokinetic profile into three types -
short, intermediate and long acting.
Regular insulin is a soluble, short-acting
insulin and since it is the only one available
in solution, it is the only insulin that may
be administered intravenously.6,7
Intermediate and long acting insulins are
suspensions of insulin that have been
modified to prolong absorption from the
site of administration. This is achieved by
producing insulin-protamine or insulin-zinc
mixtures. Insulin zinc mixtures may be
amorphous or crystalline, with the latter
having a longer duration of action.6,7 The
insulins available within the Government
Health Services (GHS) together with a
comparison of their pharmacokinetic
characteristics are summarised in Table 1.
When applying data linked to
pharmacokinetics, one must keep in mind
that most data were obtained through
assessment in healthy volunteers or in well-
controlled diabetics under specific
metabolic conditions. In actual fact, there
is wide inter and intra subject variation in
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that may alter the onset and duration of
insulin action need to be considered. This
includes the site of injection (absorption is
fastest from the abdomen and slowest from
the thigh), ambient temperature (heat
increases the rate of absorption) and
massage of the local area (increases rate of
absorption).7 Table 2 offers a comparison of
possible insulin regimens.
Administration of insulin via a
continuous subcutaneous infusion offers
intensive glycaemic control but requires
training, motivation and compliance
together with supervision from an
experienced healthcare team. Such a system
provides a basal amount of insulin (0.5-1
unit/hour) and patient-activated pulsatile
doses of insulin to cover meals. Pump
therapy may increase patient flexibility but
it is coupled by numerous problems such as
mechanical failure and hypoglycaemic and
dermatological complications. Besides, there
is no evidence that this intensive insulin
therapy offers better control than multiple
dosing.7 Patient selection criteria are
therefore cardinal to ensure safety and
success of treatment.
The sliding-scale method of insulin
dosing is sometimes used in a hospital
setting where insulin requirements may vary
drastically over a short period of time due
to stress, variable calorie intake or
inactivity. Capillary blood glucose
concentrations are measured every 4-6
hours and insulin administered accordingly
as prescribed. Sliding scales vary from
institution to institution and according to
the patient response. One needs to ensure
that the personnel involved are adequately
risk or degree of hypoglycaemia such as
missing meals, having smaller meals
than usual, increasing alcohol intake or
a sudden increase in physical exercise.
They should also be instructed on
management including the ready
availability of oral glucose if still
conscious and administration of
glucagons by relatives or companions if
unconscious.4,6 Hypoglycaemic
unawareness may be a problem in
patients who have been on insulin for a
long time or are on beta-blocker
treatment. Such patients should be
encouraged to monitor blood glucose
frequently. Despite reports that this
phenomenon is increased when
changing from animal to human insulin,
there is no evidence to support this.4,7
• Dermatological complications
include lipoatrophy (more common in
women), lipohypertrophy (more common in
men) and local skin reactions. Rotation of
injection site, use of human insulin and use
of a pure form of insulin reduces such
complications.7,17
Newer therapies
Research is currently underway to
exploit different delivery routes for insulin.
Inhaled insulin is an option where insulin is
absorbed over the lung alveolar surface.
However the bioavailability is only 10%
making this an expensive alternative.
Absorption is also very erratic with
considerable variation between
individuals.2,21 The possibility of delivering
insulin transdermally is also being
researched.22
trained in bedside blood glucose
monitoring and that meters are properly
maintained and calibrated. Strips should
be kept in tightly sealed containers to
prevent deterioration.7
A dosage regimen may involve
combination of insulin with oral agents
and this may be an option in Type II
diabetics where glycaemic control is not
adequate. Insulin is normally administered
as a dose at night to suppress the hepatic
glucose output.5 The reader is referred to
part 2 of this series for a more detailed
discussion.19
Patients may present to the pharmacy
with nausea and vomiting due to
conditions such as viral gastritis. It is very
important to advice the patient to
maintain the same dose of insulin despite
minimal food intake and advise the
patient to seek specialist medical advice
immediately. At no point should such a
patient be advised to stop insulin since
this may precipitate ketoacidosis.
Adverse effects associated with insulin
therapy
Particular problems that one needs to
look out for include:
• Hypoglycaemia may be a particular
problem in drivers and other high risk
occupations. Patients usually become
aware of dysfunction when glucose
levels fall below 3.5mmol/l. This may
be avoided by individualising the
dosage regimens, educating the
patient and regularly reviewing drug
regimens. Patients should be educated
to avoid factors that may increase the
1 All Novo products - biosynthetic recombinant DNA origin produced in Saccharomyces cerevisiae
2 All Lilly products - biosynthetic recombinant DNA origin produced in Eschericia coli
Type Brand name Active Ingredient Manufacturer Onset (hr) Peak (hr) Duration (hr) Appearance
Short Acting
Actrapid (10) Soluble insulin Novo Nordisk1 0.5-1 2-4 5-7 Clear
Humulin R (11) Soluble insulin Lilly2 0.5-1 2-4 5-7
Intermediate
Monotard (12) Mixture of Zinc amorphous & Novo Nordisk within 0.5 7-15 24 Cloudy
crystalline particles ratio 3:7
Humulin N (11) Crystalline suspension Lilly within 0.5 4-12 24 Cloudy
of human insulin with
protamine and zinc
Insulatard (13) Isophane insulin Novo Nordisk within 0.5 4-12 24 Cloudy
Long Acting
Ultratard (14) Suspension of insulin Novo Nordisk 4 8-24 28 Cloudy
zinc crystalline particles
Biphasic
Mixtard 70/30 70% isophane Novo Nordisk within 0.5 2-8 24 Cloudy
(15) 30% soluble
Humulin 70/30 As above Lilly within 0.5 2-8 24 Cloudy
(11)
Table 1: Characteristics of insulins currently available within the Government Health Services 6,7
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of cells available would be larger than a
whole pancreas.2,5,7  Problems associated
with transplantation include lack of
pancreatic donors, the need for lifelong
immunosuppression and the use of steroids
in the post-transplant period.
Transplantation is therefore limited to Type
I diabetics only when conventional therapy
significantly fails.
Though there have been numerous
developments to produce newer insulins and
alternative therapies that are more
convenient for the patient to use, it appears
that more progress is required to make
optimal use of the insulins that are
currently available.
14. Electronic Medicines Compendium for the
Professional. Specific Product Characteristics.
Ultratard. 2001. Available at:
www.emc.vhn.net/professional. Accessed on:
March, 12th, 2003.
15. Electronic Medicines Compendium for the
Professional. Specific Product Characteristics.
Mixtard 70/30. 2001. Available at:
www.emc.vhn.net/professional. Accessed on
March, 12th, 2003.
16. Campbell KR., Campbell LK, White JR. Insulin
Lispro: its role in the treatment of diabetes
mellitus. Annals of Pharmacotherapy. 1996;
30: 1263-1269.
17. White John R., Campbell KR. Diabetes Mellitus.
In: Herfindal ET, Gourley DR. Textbook of
Therapeutics: drug and disease management.
6th Edition. USA. Williams and Wilkins. 1996.
18. American Diabetes Association: Clinical
Practice Recommendations. Insulin
Administration. Diabetes Care. 2001; 24 (S1).
19. Tonna A. Management of Type II Diabetes
Mellitus - Part 2. The Chronicill. 2002;6: 5-9.
20. Dixon N. Pharmacists as part of an extended
diabetes team. PJ. 2002; 268: 469-470.
21. White JR, Campbell KR. Inhaled insulin: An
overview. Clinical Diabetes 2001;19: 13-16.
22. Medicine in the making: Insulin via a skin
patch? Health Horizons 1996; 27:18.
